CDMO– tag –
-
Lonza Boosts Biologics Manufacturing with Dual Expansion: Swiss ADC Capacity and Enhanced US Biopharma Partnership with N-1 Perfusion Technology
Industry Week USA Overview Lonza has significantly strengthened its biopharmaceutical manufacturing capabilities through a massive expansion of its Antibody-Drug Conjugate (ADC) production capacity in Switzerland and an extended long-ter... -
Cellistic Launches Integrated CDMO Services for iPSC-Derived Allogeneic Cell Therapies, Streamlining Development to GMP Manufacturing
Cellistic USA Overview Cellistic has introduced comprehensive CDMO services for iPSC-derived cell therapy manufacturing, covering development through GMP production. Their bioreactor-based Cellistic Echo platforms are engineered to ensur... -
Cellistic Unveils Specialized CDMO Services for iPSC-Derived Cell Therapies, Expediting Development from Early Stages to GMP
Cellistic Belgium Overview Cellistic is offering specialized Contract Development and Manufacturing Organization (CDMO) services tailored for iPSC-derived cell therapies. Leveraging bioreactor-based, GMP-compliant processes, the company ... -
Imunopharm Files for Shanghai STAR Market IPO, Targeting $550 Million Valuation to Expand CAR-T and CDMO Business
VCBeat China Overview Chinese biotechnology firm Imunopharm has filed for an Initial Public Offering (IPO) on the Shanghai STAR Market, targeting a valuation of 4 billion RMB (approximately $550 million). The company's pipeline includes ... -
Porton Advanced’s UC-MSC Cell Bank for Exosome Manufacturing Receives FDA Drug Master File (DMF) Acceptance
Morningstar USA Overview Porton Advanced, a CDMO, announced that its umbilical cord-derived mesenchymal stem cell (UC-MSC) cell bank for exosome manufacturing has received Drug Master File (DMF) acceptance from the U.S. FDA. This accepta... -
RoslinCT and BlueRock Therapeutics Partner to Expand Supply of Clinical-Grade iPSC Lines, Supporting Cell Therapy Development
PharmaSource UK Overview RoslinCT has announced a strategic partnership with BlueRock Therapeutics to expand access to clinical-grade iPSC lines for cell therapy developers. This collaboration integrates BlueRock's high-quality clinical-... -
Catalent and Nanoscope Expand Supply Partnership for Commercialization of Optogenetic Gene Therapy MCO-010 for Retinal Degenerative Diseases
LucidQuest Ventures USA Overview Catalent and Nanoscope Therapeutics have expanded their partnership to support the late-stage development and commercial supply of MCO-010, an optogenetic gene therapy candidate for retinal degenerative d... -
Kincell Bio Accelerates Cell Therapy Programs from Clinical Development to Commercialization with Comprehensive CDMO Services
Kincell Bio (company website) USA Overview Kincell Bio offers comprehensive and reliable Contract Development and Manufacturing Organization (CDMO) services, supporting cell therapy programs from early clinical development through commer... -
Addressing Bottlenecks in Cell and Gene Therapy Manufacturing: Urgent Need for Quality Control and Supply Chain Optimization
Drug Discovery News USA Overview Cell and gene therapy (CGT) manufacturing faces significant bottlenecks, particularly in autologous cell therapies, due to logistical delays and complex quality control challenges. Frequent issues arise w... -
SNS Insider Analysis: Viral Vector Manufacturing Market Surges as Leading CDMOs Expand Capacity with Advanced AAV and Lentiviral Technologies
SNS Insider India Overview SNS Insider's market overview highlights that the increasing number of gene therapy clinical trials and the reliance on CDMOs are driving growth in the viral vector manufacturing market. Key CDMOs like Fujifilm...
